On July 31, 2024, Zydus Lifesciences Limited announced that Mexico’s regulatory authority, COFEPRIS, has approved the marketing of MamitraTM, a biosimilar of Trastuzumab. This drug, available in 150 mg and 440 mg strengths, will be used to treat HER2-positive metastatic breast cancer, early breast cancer, and advanced gastric cancer. In Mexico, breast cancer is now …